IGC Pharma, Inc. (IGC) News
Follow IGC Pharma, Inc. (IGC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
POTOMAC, MD / / September 28, 2026 / IGC Pharma, Inc. AMEX:IGC ("IGC" or the "Company") today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead asset, IGC-AD1, for agitation in Alzheimer's
NEWS | Sep 28, 2026, 12:08 PM UTC
L
India Capital Growth Fund Reports Nav Total Return 3.1% For Six Months Ended 30 June
India Capital Growth Fund Ltd LSE:IGC
NEWS | Sep 24, 2026, 06:22 AM UTC
L
IGC Pharma reports Q2 2026 results; CALMA enrollment nears closure
IGC Pharma reports Q2 2026 results and says its CALMA Alzheimer’s trial moves within six randomizations of enrollment closure.
EARNINGS | Aug 17, 2026, 12:30 PM UTC
M
IGC Evaluates Recovery Options
IGC explores recovery options
EQUITY | Jul 29, 2026, 12:30 PM UTC
M
IGC Reduces Alzheimer's Data Time
IGC Pharma's AHA Agentic AI Platform reduces Alzheimer's data harmonization time by 90% in a representative workflow
EQUITY | Jun 23, 2026, 12:31 PM UTC